Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oxaliplatin-based chemotherapy is used to treat patients with esophageal adenocarcinoma (EAC), but no biomarkers are currently available for patient selection. We performed a prospective, clinical trial to identify potential biomarkers associated with clinical outcomes. Tumor tissue was obtained from 38 patients with resectable EAC before and after 2 cycles of oxaliplatin-fluorouracil chemotherapy. Pre-treatment mRNA expression of 280 DNA repair (DNAR) genes was tested for association with histopathological regression at surgery, disease-free survival (DFS) and overall survival (OS). High expression of 13 DNA damage repair genes was associated with DFS less than one year (P 

Original publication

DOI

10.1038/s41598-018-24232-2

Type

Journal article

Journal

Sci Rep

Publication Date

08/05/2018

Volume

8

Keywords

Adenocarcinoma, Aged, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, DNA Damage, DNA-Binding Proteins, Disease-Free Survival, Endonucleases, Esophageal Neoplasms, Female, Fluorouracil, Humans, Male, Middle Aged, Oxaliplatin, Protein Biosynthesis